{"id":828228,"date":"2025-03-20T16:06:38","date_gmt":"2025-03-20T20:06:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-update\/"},"modified":"2025-03-20T16:06:38","modified_gmt":"2025-03-20T20:06:38","slug":"nucana-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Data from the Ongoing Phase 1b\/2 Study of NUC-3373 in Combination with Pembrolizumab<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Anticipated Cash Runway Extended into Q3 2025<\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines.<\/p>\n

\u201cThroughout 2024, we shared multiple data updates from our two lead anti-cancer medicines, NUC-7738 and NUC-3373,\u201d said Hugh S. Griffith, NuCana\u2019s Founder and Chief Executive Officer. \u201cOur lead program, NUC-7738, is a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. Over the past year, we presented data highlighting NUC-7738\u2019s potential, when used in combination with pembrolizumab, to reduce tumor volume and prolong progression free survival in PD-1 inhibitor refractory and resistant patients with metastatic melanoma in the NuTide:701 study. Notably, disease control was observed in 75% (9\/12) of the patients, five of whom had tumor reductions, with two patients achieving Partial Responses. Seven of the 12 patients had a progression free survival time of greater than five months, which is highly atypical in this patient population. Equally important, the combination has shown a favorable safety profile.\u201d<\/p>\n

Mr. Griffith added, \u201cEncouraged by these findings, we are excited to further evaluate NUC-7738\u2019s potential in an expansion of the NuTide:701 study for patients with PD-1 inhibitor-resistant melanoma. We plan to initiate this expansion study and provide data updates later this year. In addition, we plan to meet with the U.S. Food and Drug Administration to seek guidance on the optimal registration strategy for NUC-7738 as we look to advance it towards approval.\u201d<\/p>\n

Mr. Griffith continued, \u201cTurning to NUC-3373, our second anti-cancer program is a targeted thymidylate synthase inhibitor with immune modulating properties. It is currently being evaluated in a Phase 1b\/2 study known as NuTide:303, which has two separate modules. One module is studying NUC-3373 in combination with pembrolizumab for patients with advanced solid tumors and the second module is studying NUC-3373 with docetaxel for patients with lung cancer. We are excited with the data we have seen from the NuTide:303 study and are particularly encouraged by the significant tumor volume reductions and prolonged progression free survival observed. Two patients achieved Partial Responses, including a patient with urothelial bladder cancer who achieved 100% reduction in their target lesions. While we were disappointed with the surprising and unexpected outcome of the NuTide:323 study of NUC-3373 in combination with leucovorin, irinotecan, and bevacizumab in patients with advanced colorectal cancer, we are continuing to evaluate further potential pathways for NUC-3373 in this challenging indication. We look forward to generating further data from this program as we work towards our mission of improving treatment outcomes for patients with cancer which drives our relentless pursuit of the development of new anti-cancer agents.\u201d<\/p>\n

Mr. Griffith concluded, \u201cIn addition to the clinical advancements we have made, we have also strengthened our intellectual property portfolio with the addition of a new granted patent by the United States Patent and Trademark Office covering NUC-7738\u2019s composition of matter. Looking ahead in 2025, we are on track to advance both NUC-7738 and NUC-3373 and are excited to provide updates on our success with these programs throughout the year.\u201d<\/p>\n

\n 2025 Anticipated Milestones<\/strong>\n <\/p>\n